For $60 million and a credit line of an additional $100 million, Merck licensed the rights to the oral formulation of vernakalant, Cardiome's atrial fibrillation treatment, and the rights to the intravenous (IV) formulation outside of North America -- Astellas owns the North American rights. That's a sizable stash, considering Cardiome had around $30 million in cash and equivalents at the end of last year.
Cardiome has the potential to receive another $640 million in milestone payments if the drugs reach clinical, regulatory, and sales goals as well as royalties on sales, so it's not like the Canadian company gave away the farm. But Cardiome isn't left with much in the pipeline; its next-farthest along drug is a phase 1 compound that it's developing to treat patients after heart attacks.
The phase 3 trials for the oral treatment would be expensive, so Cardiome had planned on licensing vernakalant out, but it might have been in a better bargaining position had things worked out better for the IV version. After a long delay, the Food and Drug Administration turned down the marketing application for the drug and asked for more information last August.
With so much cash in their pockets, I expect drugmakers like GlaxoSmithKline
Maybe this Foolishness can help you earn some cash:
Johnson & Johnson and Glaxo are Income Investor recommendations. To see how dividend-paying stocks can offer both secure income and the opportunity for growth, take a free look at this newsletter with a 30-day free trial.